Cropley VL, Fujita M, Innis RB, Nathan PJ (2006). Molecular
imaging of the dopaminergic system and its association
with human cognitive function. Biological Psychiatry 59,
898–907.
Floresco SB, Magyar O (2006). Mesocortical dopamine
modulation of executive functions: beyond working
memory. Psychopharmacology 188, 567–585.
Fusar Poli P, Perez J, Broome M, Borgwardt S, Placentino A
(2007). Neurofunctional correlates of vulnerability to
psychosis: a systematic review and meta-analysis.
Neuroscience & Biobehavioral Reviews 31, 465–484.
Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N,
Buchholz HG (2003). Subchronic haloperidol
downregulates dopamine synthesis capacity in the brain of
schizophrenic patients in vivo. Neuropsychopharmacology
28, 787–794.
Howes OD, Montgomery AJ, Asselin MC, Murray RM,
Valli I, Grasby P (in press). Elevated striatal dopamine
function linked to prodromal signs of schizophrenia.
Archives of General Psychiatry.
McGlashan TH, Zipursky RB, Perkins D, Addington J,
Miller T (2006). Randomized, double-blind trial of
olanzapine versus placebo in patients prodromally
symptomatic for psychosis. American Journal of Psychiatry
163, 790–799.
McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S
(2002). Randomized controlled trial of interventions
designed to reduce the risk of progression to first-episode
psychosis in a clinical sample with subthreshold
symptoms. Archives of General Psychiatry 59, 921–928.
McGowan S, Lawrence AD, Sales T, Quested D, Grasby P
(2004). Presynaptic dopaminergic dysfunction in
schizophrenia: a positron emission tomographic
[18F]fluorodopa study. Archives of General Psychiatry 61,
134–142.
McGuire P, Howes OD, Stone J, Fusar-Poli P (2008).
Functional neuroimaging in schizophrenia: diagnosis
and drug discovery. Trends in Pharmacological Science
29, 91–98.
Tanaka S (2006). Dopaminergic control of working memory
and its relevance to schizophrenia: a circuit dynamics
perspective. Neuroscience 139, 153–171.
Vernaleken I, Kumakura Y, Cumming P, Buchholz HG,
Siessmeier T, Stoeter P (2006). Modulation of
[18F]fluorodopa (FDOPA) kinetics in the brain of healthy
volunteers after acute haloperidol challenge. Neuroimage
30, 1332–1339.
Weinhard K (1998). The Theory and Practice of 3D PET. In:
Bendriem B, Townsend DW(Eds), pp. 150–154. Dordrecht :
Kluwer Academic Publishers.
Yung A, Phillips L, McGorry P, Ward J, Donovan K (2002).
Comprehensive Assessment of At Risk Mental States
(CAARMS). Melbourne: PACE Clinic, Department of
Psychiatry, University of Melbourne.
Yung AR, Phillips LJ, Yuen HP, Francey SM,McFarlane CA
(2003). Psychosis prediction: 12-month follow up of a
high-risk (‘prodromal’) group. Schizophrenia Research
60, 21–32.